X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs AUROBINDO PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS AUROBINDO PHARMA NOVARTIS/
AUROBINDO PHARMA
 
P/E (TTM) x 298.1 14.9 1,996.5% View Chart
P/BV x 25.4 3.9 658.7% View Chart
Dividend Yield % 1.4 0.4 354.8%  

Financials

 NOVARTIS   AUROBINDO PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-17
AUROBINDO PHARMA
Mar-17
NOVARTIS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs855895 95.5%   
Low Rs666622 107.0%   
Sales per share (Unadj.) Rs219.0254.6 86.0%  
Earnings per share (Unadj.) Rs19.139.3 48.6%  
Cash flow per share (Unadj.) Rs20.346.6 43.6%  
Dividends per share (Unadj.) Rs10.002.50 400.0%  
Dividend yield (eoy) %1.30.3 399.1%  
Book value per share (Unadj.) Rs307.0160.0 191.9%  
Shares outstanding (eoy) m29.96585.88 5.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.53.0 116.5%   
Avg P/E ratio x39.819.3 206.1%  
P/CF ratio (eoy) x37.516.3 230.0%  
Price / Book Value ratio x2.54.7 52.2%  
Dividend payout %52.46.4 822.6%   
Avg Mkt Cap Rs m22,779444,390 5.1%   
No. of employees `0000.714.0 4.8%   
Total wages/salary Rs m1,39317,678 7.9%   
Avg. sales/employee Rs Th9,736.210,667.8 91.3%   
Avg. wages/employee Rs Th2,066.81,264.3 163.5%   
Avg. net profit/employee Rs Th849.01,645.8 51.6%   
INCOME DATA
Net Sales Rs m6,562149,157 4.4%  
Other income Rs m7021,159 60.5%   
Total revenues Rs m7,264150,316 4.8%   
Gross profit Rs m25934,343 0.8%  
Depreciation Rs m364,276 0.8%   
Interest Rs m7667 1.1%   
Profit before tax Rs m91730,558 3.0%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3457,597 4.5%   
Profit after tax Rs m57223,012 2.5%  
Gross profit margin %3.923.0 17.1%  
Effective tax rate %37.624.9 151.3%   
Net profit margin %8.715.4 56.5%  
BALANCE SHEET DATA
Current assets Rs m9,73192,062 10.6%   
Current liabilities Rs m1,83066,223 2.8%   
Net working cap to sales %120.417.3 695.0%  
Current ratio x5.31.4 382.4%  
Inventory Days Days49106 45.9%  
Debtors Days Days2568 37.2%  
Net fixed assets Rs m5762,919 0.1%   
Share capital Rs m141586 24.0%   
"Free" reserves Rs m9,05693,133 9.7%   
Net worth Rs m9,19693,719 9.8%   
Long term debt Rs m01,814 0.0%   
Total assets Rs m11,499162,494 7.1%  
Interest coverage x128.446.8 274.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.9 62.2%   
Return on assets %5.014.6 34.6%  
Return on equity %6.224.6 25.3%  
Return on capital %10.132.7 30.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12975,838 0.2%   
Fx outflow Rs m1,73430,224 5.7%   
Net fx Rs m-1,60545,613 -3.5%   
CASH FLOW
From Operations Rs m-38032,786 -1.2%  
From Investments Rs m4,208-17,870 -23.5%  
From Financial Activity Rs m-3,318-19,153 17.3%  
Net Cashflow Rs m510-4,239 -12.0%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.0 25.2%  
FIIs % 1.6 27.7 5.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.2 210.8%  
Shareholders   41,647 69,601 59.8%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALEMBIC LTD  SHASUN PHARMA  PFIZER  FDC LTD.  SUN PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 20, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS